- 20 October
-
On October 10, 2025, a representative delegation visited the Medsintez Plant. Among the visitors, there were members of the State Duma of the Russian Federation, representatives of the Government and Legislative Assembly of the Sverdlovsk Region, the head of the Novouralsk Urban District, and leading regional experts in the field of medical science. The main purpose of the visit was to assess the enterprise's success in import-substituting drug production, become familiar with its brand-new products, and discuss development options of the pharmaceutical industry in the region.
- 09 September
-
On September 3, 2025, Denis Pasler, Acting Governor of the Sverdlovsk Region, paid a working visit to Medsintez Plant LLC, one of the systemic companies of the Russian Federation. The purpose of the visit was to assess the scale of import substitution in pharmaceutical production, get acquainted with the latest developments of the plant, and discuss prospects for the regional pharmaceutical industry.
- 12 August
-
Experts from the Russian Ministry of Health have included the TRIAZAVIRIN® antiviral drug in the guidelines «Prevention, Diagnosis and Treatment of the Novel Coronavirus Infection COVID-19» (version No. 19 dated 27/5/2025).
- 17 June
-
From May 20 to 22, the first Eurasian International Medical Forum was held in Ekaterinburg. The event was dedicated to the 80th anniversary of Victory in the Great Patriotic War. The Forum brought together over 1,000 participants and 250 experts from Russia, India, China and Belarus. Medsintez Plant took an active part in scientific program of the Forum and demonstrated its latest developments in the field of import-substituting drugs.
- Home
- Cluster members
- As & Co Pharm group LLC
As & Co Pharm group LLC
The enterprise As & Co Pharm group LLC is the Ural pharmaceutical company Asco Pharm. The company is a portfolio project of the Ural Federal University (UrFU) Innovation Development Fund, UrFU Innovation Infrastructure and INNOPORT startup studio. Asco Pharm has been researching and developing medicines and dietary supplements for over 15 years. The flagship project of the company is the development of an innovative original drug for the prevention and treatment of osteoporosis, which is in the process of going through the necessary clinical and bureaucratic procedures. In this regard, in order to accelerate the commercialization of the project, the company, based on this drug, brought to the market an innovative dietary supplement REOCYTAN Calcium- Magnesium-D3. Even during the research period, the project showed excellent results, opening up a completely new approach in the fight against osteoporosis and calcium deficiency. The drug uses a patented formula that has no analogues in the world and an innovative technology for delivering calcium to bone tissue. The project has received great interest from the scientific community in Russia and abroad. With this project, the company won the largest business accelerator in the Urals of the Ural Federal University in 2018 And in 2020, Reocytan won the prestigious medical innovation competition held by TIPA in South Korea. Asco Pharm's portfolio also includes more than 20 developments at various stages: recovery after strokes and severe brain injuries, tissue repair after injuries or severe pathologies (heart failure, AECB, SARS, COVID, etc.) oncoprophylaxis technology, technology for removal of hepatitis B virus complicated by D, technology for preventing an autoimmune response in pneumonia of various etiologies, a line of products that suppress muscular dystrophy, etc.
The company is planning to bring several more brands to the market in the next few years.
Tel.: +7 (922)-115-30-63
E-mail: info@ascopharm.ru
www.ascopharm.ru
www.reocytan-calcium.com
